“Drug Delivery Technologies market set to grow to $355bn by 2024” says new Visiongain report

28 February 2019
Pharma

Visiongain has published a new pharma report Drug Delivery Technologies Market Forecast 2019-2029: Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular, Nasal/Buccal Drug Delivery Technologies, Biologics, Vaccines.

The Drug Delivery Technologies Market is estimated to grow at a CAGR of 7.8% from 2019 to 2029, driven by exciting new technologies and the potential of extending product life by developing new formulations.

Over the last ten years, the global drug delivery technologies market has witnessed a significant increase in the number of drug delivery companies offering innovative technologies to pharmaceutical manufacturers. Drug delivery technology is an important enabling technology for pharmaceutical products. These platforms are often used by pharmaceutical companies for various reasons, which importantly include the extension of product lifecycle.

There are companies developing new technologies to take advantage of the potential for growth that is abundant in this market. This rapidly expanding market provides growth opportunities for developers willing to invest in R&D. This report profiled the selected companies: 3M, Alkermes PLC, Altea Therapeutics Corporation, Antares Pharma Inc., Applied Pharma Research S.A. (APR), Becton, Dickinson & Company and others.

The lead analyst commented that "The potential use of drug delivery technologies in product lifecycle management and the enhancement of drug efficacy in many therapeutic sectors will act as drivers for growth of the market over the coming decade. This is mainly due to the rising demand from pharmaceutical companies looking to innovate and improve the marketability of their drugs. The potential of extending the patent life of a drug by developing new formulations will act as a driver for the market as it will prompt pharma companies to seek to maximise the return on investment from each marketed drug."

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain publishes Constipation Nutraceuticals Market Report 2020-2030

Nutraceuticals are the products that provide medicinal and health benefits to the people. These products provide additional nutritional value to the foodstuff.

01 June 2020

Read

“Precision Medicine Market is Poised to Surpass US$67 billion in 2020” says new Visiongain report

Visiongain anticipates that the global precision medicine market is projected to witness a CAGR of 12% over the forecast period from 2020 to 2030. The global precision medicine market is anticipated to surpass US$ 67 billion in 2020 and is further projected to surpass US$ 200 billion in 2030.

27 May 2020

Read

Visiongain publishes Colon Targeting Drug Delivery Market Report 2020-2030

The global colon targeting drug delivery market is projected to grow at a CAGR of 8.07% in the first half of the forecast period. Visiongain anticipate that the global market will witness a CAGR of 9.23% during the forecast period 2020 to 2030.

27 May 2020

Read

“The global automation in biopharma market is estimated to reach USD 1.23 billion by 2025” says new Visiongain report

The automation in biopharma industry market is estimated to grow at a CAGR of 4.3% over the forecast period.

22 May 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever